Clinical Trial

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)

Brief Summary: In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475)

Key Eligibility Criteria:

• Histologically or cytologically-documented, advanced solid tumor
• Radiologically-measurable disease
• Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
• Progression of tumor or intolerance to therapies known to provide clinical benefit
• Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment excluded